Patent · US Active

NFAT binding polynucleotides

US11618773B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Universität Heidelberg · DE

Inventors

Markus Hecker · Saskatoon, CA
Andreas Wagner · Klosterneuburg, AT
Andreas Jungmann · Neckargemünd, DE
Oliver Müller · Dossenheim, DE
Anca Remes · Kiel, DE
Hugo Katus · Heidelberg, DE

Key dates

Filing date	Jan 14, 2019
Grant date	Apr 4, 2023
Priority date	—
Expiry date	Jan 14, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence separated by a spacer sequence, to said polynucleotide for use in treating and/or preventing disease, and to viral particles, compositions, and uses related thereto. The present invention further relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence for use in treating and/or preventing an NFAT-mediated disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.